Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Parkinson's Disease

Free Subscription 16.02.2026 1 Ann Neurol 3 BMC Neurol 1 Brain Res 1 Exp Neurol 8 Mov Disord 2 Nat Rev Neurol 1 Neurobiol Dis 2 Neuroscience 1 PLoS Comput Biol 1 Rev Neurol (Paris)

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Neurol

1. FIGURA M, Milanowski L, Nowak JM, Antoniak A, et al
   Safety and Efficacy of Fecal Microbiota Transplantation in Alleviating Symptoms of Parkinson's Disease: A Randomized, Placebo-Controlled, Double-Blinded Study.
   Ann Neurol. 2026 Feb 12. doi: 10.1002/ana.78153.
   PubMed         Abstract available
   
   

   
   BMC Neurol

2. LI J, Zhou R, Deng J, Zhou H, et al
   Correction: Sleep disorders in parkinson's disease: evaluating pharmacological treatments through systematic review and meta-analysis.
   BMC Neurol. 2026;26:84.
   PubMed        
   
   
3. HAAS J, Rogge A, Otto B, Michel N, et al
   Preventive measures for Parkinson's disease: insights into motivation and barriers from the patients' perspective.
   BMC Neurol. 2026 Feb 11. doi: 10.1186/s12883-026-04703.
   PubMed        
   
   
4. MA H, Wang H, Zhu Y, Liang L, et al
   Utility of gait biomarkers in screening for obstructive sleep apnea among patients with Parkinson's disease: a cross-sectional study.
   BMC Neurol. 2026 Feb 9. doi: 10.1186/s12883-026-04700.
   PubMed        
   
   

   
   Brain Res

5. ERMINDA SCHREINER G, Smolski Dos Santos L, Berny Pereira C, Pereira de Oliveira C, et al
   Neuroprotective and memory-enhancing effects of Aloysia gratissima extract and rutin in an MPTP-induced model of Parkinson's disease.
   Brain Res. 2026;1877-1878:150202.
   PubMed         Abstract available
   
   

   
   Exp Neurol

6. ZHONG J, Xu J, Xue J, Qiu Z, et al
   Phosphodiesterase 4 as a therapeutic target in Parkinson's disease recent advances.
   Exp Neurol. 2026 Feb 9:115680. doi: 10.1016/j.expneurol.2026.115680.
   PubMed         Abstract available
   
   

   
   Mov Disord

7. MIKHAEL D, Deutsch S, Mehta J, Wang S, et al
   Preoperative Functional Connectivity Predicts Antiparkinson Drug Change after Deep Brain Stimulation.
   Mov Disord. 2026;41:168-178.
   PubMed         Abstract available
   
   
8. DARGVAINIENE J, Helmers AK, Naumann J, Gless CA, et al
   Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.
   Mov Disord. 2026;41:241-246.
   PubMed         Abstract available
   
   
9. WILKEN M, Granda L, Cruz I, Rossi M, et al
   The Role of Basal Ganglia Theta Oscillations in Predicting the Onset of Levodopa-Induced Dyskinesias.
   Mov Disord. 2026;41:228-233.
   PubMed         Abstract available
   
   
10. NEILSON LE, Lin C, Mishra A, Scott GD, et al
    Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease.
    Mov Disord. 2026 Feb 9. doi: 10.1002/mds.70218.
    PubMed         Abstract available
    
    
11. BARMPA K, Saraiva C, Zagare A, Tuzza M, et al
    Parkinson's Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation.
    Mov Disord. 2026 Feb 11. doi: 10.1002/mds.70176.
    PubMed         Abstract available
    
    
12. CARRILLO M, Hernandez-Pinedo N, Zaldivar-Diez J, Perez-Santos I, et al
    Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkey Model of Parkinson's Disease.
    Mov Disord. 2026 Feb 12. doi: 10.1002/mds.70209.
    PubMed         Abstract available
    
    
13. LAMOS M, Zackova A, Ulcak D, Gurka B, et al
    Local Field Aperiodic Spectral Power Modulated by Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2026 Feb 13. doi: 10.1002/mds.70232.
    PubMed         Abstract available
    
    
14. GU SC, Sun QY, Zhang W, Shen CY, et al
    Cell-Type-Specific Causal Inference Unveils Novel Targets for Parkinson's Disease.
    Mov Disord. 2026 Feb 13. doi: 10.1002/mds.70223.
    PubMed         Abstract available
    
    

    
    Nat Rev Neurol

15. TEIXEIRA-DOS-SANTOS D, Tan AH, Okubadejo N, Kalia LV, et al
    Bridging global diversity gaps in Parkinson disease research.
    Nat Rev Neurol. 2026 Feb 10. doi: 10.1038/s41582-026-01183.
    PubMed         Abstract available
    
    
16. TOLOSA E, Poewe W, Noyce AJ, Svenningsson P, et al
    Towards biomarker-based diagnosis of Parkinson disease.
    Nat Rev Neurol. 2026 Feb 13. doi: 10.1038/s41582-026-01185.
    PubMed         Abstract available
    
    

    
    Neurobiol Dis

17. LIU J, Yu D, Liu Y, Yong Y, et al
    Cholinergic neurotransmission underlying visual hallucinations in Parkinson's disease: Integration of multimodal evidence and translational approaches.
    Neurobiol Dis. 2026;220:107316.
    PubMed         Abstract available
    
    

    
    Neuroscience

18. LI M, Guo R, Liu M, Xu L, et al
    Glutamate chemical exchange saturation transfer imaging reveals cerebellar glutamatergic alterations in Parkinson's disease subtypes.
    Neuroscience. 2026 Feb 11:S0306-4522(26)00112.
    PubMed         Abstract available
    
    
19. ZHANG Y, Liu T, Li X, Liu S, et al
    Neuroprotective effects of idebenone in a zebrafish model of Parkinson's disease via regulating autophagy, mitigating apoptosis and oxidative stress.
    Neuroscience. 2026 Feb 13:S0306-4522(26)00111.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

20. AHMADIPOUR M, Fattorini F, Meneghetti N, Mazzoni A, et al
    In silico model of basal ganglia deep brain stimulation in Parkinson's disease captures range of effective parameters for pathological beta power suppression.
    PLoS Comput Biol. 2026;22:e1013280.
    PubMed         Abstract available
    
    

    
    Rev Neurol (Paris)

21. DESNOYERS M, Bonjour M, Metereau E, Danaila T, et al
    DBS-related infections in Parkinson's disease: Incidence, risk factors, management and outcome.
    Rev Neurol (Paris). 2026 Feb 13:S0035-3787(26)00028.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Parkinson's Disease is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum